The short version of visceral adipose tissue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-19. Anything still debated is marked as such rather than presented as settled.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
In the drug discovery process of a 5-HT2C agonist, a pharmacophore module has been used to discover novel 5-HT2C receptor ligands. The pharmacophore has four features; one aromatic ring, two hydrophobic features and one positive ionizable feature. Figure 4 shows an example of a compound that fits the agonist pharmacophore perfectly. The nitrogen atom of piperazine fits the positive ionizable feature, the benzofuran part fits the aromatic ring and one hydrophobic, and the trifluoromethane part fits another hydrophobic feature of the pharmacophore.
=== Tizard committee === The need to research better forms of air defense prompted Harry Wimperis to press for the formation of a study group to consider new concepts. Lord Londonderry, then Secretary of State for Air, approved the formation of the Committee for the Scientific Survey of Air Defence in November 1934, asking Henry Tizard to chair the group, which thus became better known to history as the Tizard Committee. When Wimperis sought an expert in radio to help judge the death-ray concept, he was naturally directed to Watt. He wrote to Watt "on the practicability of proposals of the type colloquially called 'death ray'". The two met on 18 January 1935, and Watt promised to look into the matter. Watt turned to Wilkins for help but wanted to keep the underlying question a secret. He asked Wilkins to calculate what sort of radio energy would be needed to raise the temperature of 8 imperial pints (4.5 L) of water at a distance of 5 kilometres (3.1 mi) from 98 to 105 °F (37 to 41 °C). To Watt's bemusement, Wilkins immediately surmised this was a question about a death ray. He made a number of back-of-the-envelope calculations demonstrating the amount of energy needed would be impossible given the state of the art in electronics. According to R. V.
United Germany was considered the enlarged continuation of West Germany, so it retained its memberships in international organisations. Based on the Berlin/Bonn Act of 1994, Berlin again became the capital of Germany, while Bonn obtained the unique status of a Bundesstadt (federal city), retaining some federal ministries. The relocation of the government was completed in 1999, and modernisation of the East German economy was scheduled to last until 2019. Since reunification, Germany has taken a more active role in the European Union, signing the Maastricht Treaty in 1992 and the Lisbon Treaty in 2007, and co-founding the eurozone. Germany sent a peacekeeping force to secure stability in the Balkans and sent German troops to Afghanistan as part of a NATO effort to provide security in that country after the ousting of the Taliban. In the 2005 elections, Angela Merkel became the first female chancellor. In 2009, the German government approved a €50 billion stimulus plan. Among the major German political projects of the early 21st century are the advancement of European integration, the country's energy transition (Energiewende) for a sustainable energy supply, the debt brake for balanced budgets, measures to increase the fertility rate (pronatalism), and high-tech strategies for the transition of the German economy, summarised as Industry 4.0. During the 2015 European migrant crisis, the country took in over a million refugees and migrants.
Fibrinogen (coagulation factor I) is a glycoprotein complex, produced in the liver, that circulates in the blood of all vertebrates. During tissue and vascular injury, it is converted enzymatically by thrombin to fibrin and then to a fibrin-based blood clot. Fibrin clots function primarily to occlude blood vessels to stop bleeding. Fibrin also binds and reduces the activity of thrombin. This activity, sometimes referred to as antithrombin I, limits clotting. Fibrin also mediates blood platelet and endothelial cell spreading, tissue fibroblast proliferation, capillary tube formation, and angiogenesis and thereby promotes revascularization and wound healing. Reduced and/or dysfunctional fibrinogens occur in various congenital and acquired human fibrinogen-related disorders. These disorders represent a group of rare conditions in which individuals may present with severe episodes of pathological bleeding and thrombosis; these conditions are treated by supplementing blood fibrinogen levels and inhibiting blood clotting, respectively. These disorders may also be the cause of certain liver and kidney diseases. Fibrinogen is a "positive" acute-phase protein, i.e. its blood levels rise in response to systemic inflammation, tissue injury, and certain other events. It is also elevated in various cancers. Elevated levels of fibrinogen in inflammation as well as cancer and other conditions have been suggested to be the cause of thrombosis and vascular injury that accompanies these conditions.
Sources: en.wikipedia.org
==== Bureaucratic/corporate operations ==== Bureaucratic/corporate organized crime groups are defined by the general rigidity of their internal structures. They focus more on how the operation works, succeeds, sustains itself or avoids retribution, they are generally typified by:
==== Cause ==== Cause, the open and closed approaches to rhinoplastic correction resolve: (i) nasal pathologies (diseases intrinsic and diseases extrinsic to the nose); (ii) an unsatisfactory aesthetic appearance (disproportion); (iii) a failed primary rhinoplasty; (iv) an obstructed airway; and (v) congenital nose defects and deformities.
== Operations == A&W is the only major fast-food chain in the United States to be owned entirely by franchisees since the 2011 sale from Yum! Brands to A Great American Brand, LLC., which is mostly under the control of the National A&W Franchisee Association (NAWFA). The current owners rely heavily on single-brand restaurants, in contrast to combined, co-branded restaurants, which came from prior administrations. As of December 2021, there were 900 restaurants in the US and Asia. In the United States alone, the states with the most restaurants are California, followed by Wisconsin and Michigan. As of year-end 2023, A&W has 455 franchised restaurants in the US market alone. The number of co-branded locations has been on the decline with 243 such units. As of January 2025, A&W has made it to the Franchise 500 list for six consecutive years, standing at 210th place in the 2024 ranking. The number of restaurants in the United States and in Asia is almost equiparable, with the chain steadily decreasing its number of units in the United States and increasing elsewhere, a trend that has been following since 2015.
== Further reading == The Folger Way: Coffee Pioneering Since 1850, by Ruth Waldo Newhall (1910–2003), married to Scott Newhall (1914–1992), late of the San Francisco Chronicle, J.A. Folger (publisher) (1961); OCLC 5838971
If two neighboring carbon atoms are labeled, a doublet of doublets may degenerate into a triplet if the doublet splittings are equal. The drawbacks to using NMR techniques for metabolic flux analysis purposes is that it is different from other NMR applications because it is a rather specialized discipline. An NMR spectrometer may not be directly available for all research teams. The optimization of NMR measurement parameters and proper analysis of peak structures requires a skilled NMR specialist. Certain metabolites also may require specialized measurement procedures to obtain additional isotopomer data. In addition, specially adapted software tools are needed to determine the precise quantity of peak areas as well as identifying the decomposition of entangled singlet, doublet, and triplet peaks. As opposed to nuclear magnetic resonance, mass spectrometry (MS) is another method that is more applicable and sensitive to metabolic flux analysis experiments. MS instruments are available in different variants. Different from two-dimensional nuclear magnetic resonance (2D-NMR), the MS instruments work directly with hydrolysate. In gas chromatography-mass spectrometry (GC-MS), the MS is coupled to a gas chromatograph to separate the compounds of the hydrolysate. The compounds eluting from the GC column are then ionized and simultaneously fragmented. The benefit in using GC-MS is that not only are the mass isotopomers of the molecular ion measured but also the mass isotopomer spectrum of several fragments, which significantly increases the measured information.
Sources: en.wikipedia.org
== Support of women scientists == When Mary Osborn returned to Europe after years in the US, she was surprised to find that European science, technology, engineering, and mathematics (STEM fields) had not opened doors to women as she had experienced in America. She was quoted in an article in Science in 1994 to the effect that women's role in Germany was still "kinder, kuche, kirch" (children, kitchen, church.) In 1992, she had written a protest letter in response to an editorial in Nature that had claimed child care issues were chiefly responsible for the leaky pipeline for women in science, not discrimination. As a woman without children who had experienced no gender discrimination early in her career but had seen differential treatment of men and women in science later, she did not find this argument convincing, and she was appalled to find out that Europe had collected little or no data on rates of success of women in science. Partly because Osborn objected to this situation, the European Commission (EC) appointed her co-chair of a working group to investigate the status of European women scientists and scientists in training and in employment and to prepare a report. The outcome was the European Technology Assessment Network (ETAN) Report on Women in Science, published in 2006, which identified a number of reasons why women dropped out of science and served as a blueprint for Europeans who wished to fix this problem. She noted in 2012 that there was still a leaky pipeline for women scientists in Germany.
== Research == Insulin was discovered in 1921, by Frederick Banting, Charles Best and John Macleod at the University of Toronto. At a time when most child diabetics lived no more than months or a few years, insulin offered the hope of extending lives. Somogyi worked with Philip A. Shaffer and Edward Adelbert Doisy on insulin preparation and insulin's use in the treatment of diabetes. He developed a method for extracting insulin from the pancreases of dogs. In 1922 doctors treated the first diabetic American child, a baby boy, with Somogyi's insulin. Somogyi also developed a quicker, less expensive method for screening for diabetes, using sodium carbonate, urine, and heat. This led to the development of popular tests, including several varieties of urine sugar comparator from the Aloe Company of Saint Louis, Missouri. Urine Sugar Test kits were also produced by Eli Lilly and Company.
Major Fishback's courageous letter shed light on the atrocities that were being committed—shamefully—in the name of our nation. ... After reports emerged from horrific abuses at Abu Ghraib in Iraq, I tried for a year and a half to pass legislation to make it clear that cruel, inhuman, and degrading treatment of detainees was illegal. Two military heroes, my former colleague Senator John McCain and Major Fishback, turned the tide in this effort.
Magnetic resonance spectroscopy (MRS) is used to measure the levels of different metabolites in body tissues, which can be achieved through a variety of single voxel or imaging-based techniques. The MR signal produces a spectrum of resonances that corresponds to different molecular arrangements of the isotope being "excited". This signature is used to diagnose certain metabolic disorders, especially those affecting the brain, and to provide information on tumor metabolism. Magnetic resonance spectroscopic imaging (MRSI) combines both spectroscopic and imaging methods to produce spatially localized spectra from within the sample or patient. The spatial resolution is much lower (limited by the available SNR), but the spectra in each voxel contains information about many metabolites. Because the available signal is used to encode spatial and spectral information, MRSI requires high SNR achievable only at higher field strengths (3 T and above). The high procurement and maintenance costs of MRI with extremely high field strengths inhibit their popularity. However, recent compressed sensing-based software algorithms (e.g., SAMV) have been proposed to achieve super-resolution without requiring such high field strengths.
== External links == Genome-based Peptide Fingerprint Scanning (GFS) Documentation Archived 27 September 2013 at the Wayback Machine Facebook link to "Genome-based Peptide Fingerprint Scanning" Explanation of MS/MS in relation to MASCOT
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.